Syndax Pharmaceuticals (SNDX) Restructuring Costs (2024 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Restructuring Costs of $4.8 million for Q4 2025, down 8.45% year-over-year from $5.2 million in Q4 2024, and down 47.3% quarter-over-quarter from $9.1 million in Q3 2025.
Powered by 
Analysis
Syndax Pharmaceuticals (SNDX) Restructuring Costs (2024 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Restructuring Costs history runs 2 years deep, the most recent figure standing at $4.8 million for Q4 2025.
- In Q4 2025, Restructuring Costs fell 8.45% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $18.9 million (down 10.49% YoY), while the FY2025 annual figure was $23.3 million, up 34.33% from the prior year.
- Restructuring Costs for Q4 2025 stood at $4.8 million, down from $9.1 million in the prior quarter.
- The five-year high for Restructuring Costs was $11.8 million in Q2 2024, with the low at $247000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Syndax Pharmaceuticals | 1.83 Bn | 1.29 Bn | 60.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.87 Mn |
| Dec 31, 2025 | 4.80 Mn |
| Sep 30, 2025 | 9.11 Mn |
| Jun 30, 2025 | 4.99 Mn |
| Mar 31, 2025 | 247,000.00 |
| Dec 31, 2024 | 5.24 Mn |
| Sep 30, 2024 | 3.85 Mn |
| Jun 30, 2024 | 11.77 Mn |